Clinical Trial Update: An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia [Phase 3]

View source ↗

Summary

Open-label, long-term Phase 3 trial assessing aripiprazole intramuscular depot in schizophrenia; completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• aripiprazole intramuscular depot (aripiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2020-01-06